← All trials
NCT04483505
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 25, 2020
- Primary completion
- Feb 3, 2023
- Completion date
- Feb 3, 2023
- First posted
- Jul 23, 2020
- Last posted
- Dec 2, 2020
- Enrollment
- 19
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Fundacion CRIS de Investigación para Vencer el CáncerLead sponsor
- PfizerCollaborator
- BayerCollaborator
- Universidad Complutense de MadridOverall official - principal investigator
- Universidad Autonoma de MadridOverall official - principal investigator
- Apices Soluciones S.L.Collaborator
- Centro Nacional de Investigaciones OncológicasOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.